Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_1
3
33%
Ph phase_4
1
11%
Ph phase_3
1
11%
Ph not_applicable
3
33%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (37.5%)
Phase 31 (12.5%)
Phase 41 (12.5%)
N/A3 (37.5%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completednot_applicable

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

NCT05199714
completednot_applicable

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

NCT04163874
completedphase_1

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
completed

Effect of Fiasp® in Type 1 Diabetes Treatment

NCT03895515
completednot_applicable

Fast Advanced Closed-Loop Therapy

NCT04853030
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05199714Not Applicable

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

Completed
NCT04163874Not Applicable

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

Completed
NCT05184868Phase 1

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Completed
NCT03895515

Effect of Fiasp® in Type 1 Diabetes Treatment

Completed
NCT04853030Not Applicable

Fast Advanced Closed-Loop Therapy

Completed
NCT03554486Phase 4

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Completed
NCT03977727Phase 3

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Completed
NCT03959514Phase 1

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Completed
NCT03179332Phase 1

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9